STEP-HFpEF — Heart Failure Trial

Source: New England Journal of Medicine (2023).

Key finding: Improved heart failure symptoms and exercise.

Part of GLP1Score's 20-study clinical evidence library — the peer-reviewed research powering our GLP-1 eligibility scoring engine.

Related Reading

Semaglutide in India — Complete Guide
Semaglutide Drug Monograph (dosing, contraindications)
Who Qualifies for Semaglutide in India
Semaglutide for the Treatment of Obesity: A Comprehensive Review
Semaglutide in Heart Failure with Preserved Ejection Fraction and Diabetes (STEP-HFpEF DM)
Weight Regain After Discontinuation of GLP-1 Receptor Agonists: A Systematic Review

Take the Free Eligibility Assessment → · Compare All 18+ Brands